At the American Urological Association 2026 Annual Meeting (May 15-18, Washington D.C.), researchers presented a real-world cohort analysis of 469 men with hypogonadism that overturns a common assumption: the testosterone therapy modality you choose materially changes how much your symptoms improve, even when serum testosterone reaches the same range.
The IP22-08 abstract is one of the first large datasets to track symptom-specific outcomes across injectable testosterone, topical gels, and clomiphene citrate at scale. The signal is clear — modality matters, and the differences are clinically meaningful for libido, energy, and mood.
Key Takeaways
AUA 2026 cohort of 469 men compared symptom improvement across TRT modalities
Injectable testosterone produced the highest rates of symptomatic response
Clomiphene citrate showed lower symptom improvement despite raising labs, partly due to disproportionate estradiol rise
Topical gels fell between injections and clomiphene
Labs in range does not mean symptoms resolved — modality choice matters
Pick a clinic that offers multiple modalities and is willing to switch if response is poor
The IP22-08 abstract — presented by a group of urology researchers at AUA 2026 — pulled real-world electronic health record data from 469 men diagnosed with hypogonadism and started on one of three treatment modalities:
Injectable testosterone (mostly testosterone cypionate weekly or twice-weekly)
Clomiphene citrate (off-label oral SERM that stimulates the HPG axis)
The endpoints were not just lab values. The researchers tracked symptom-specific improvement using validated hypogonadism symptom inventories, looking at libido, energy, mood, and erectile function as separate domains.
The headline finding: men on injectable testosterone reported the highest rates of symptomatic improvement. Men on clomiphene citrate reported lower rates of symptom improvement. Topical gels fell in between. This pattern held even after adjusting for baseline testosterone, age, and BMI.
Why Clomiphene Lagged
The clomiphene result is the most surprising part of the cohort. Clomiphene works by blocking estrogen receptor feedback at the hypothalamus, which increases LH and FSH release, which drives endogenous testosterone production. The numbers move — but they move differently than with exogenous testosterone.
Two mechanisms explain the symptom gap:
1. Modest testosterone elevation. Clomiphene typically raises total testosterone by 200 to 350 ng/dL — a real change, but smaller than what most men get on weekly injections. The lower delta translates to a smaller symptomatic shift.
2. Disproportionate estradiol rise. Because clomiphene stimulates the whole HPG axis, estradiol climbs alongside testosterone. The testosterone-to-estradiol ratio often shifts in an unfavorable direction. Men who are sensitive to elevated estradiol report symptoms — water retention, mood changes, blunted libido — even with "normal" testosterone numbers. See the estradiol management on TRT and testosterone-estradiol ratio guides for the details.
Why Gels Sit in the Middle
Topical gels deliver testosterone transdermally, with absorption rates of roughly 10 percent. The advantages — steady serum levels, no needles, no peaks and troughs — are real, but the trade-offs help explain why gels underperformed injections in this cohort:
Absorption variability. Skin thickness, application site, body fat, and even shower timing affect how much drug actually reaches circulation.
Lower peak levels. Injections produce supraphysiologic peaks for 24 to 48 hours that drive stronger libido and energy response. Gels avoid peaks entirely.
Transfer risk. Patients sometimes underdose to avoid skin transfer to partners or children, which keeps levels lower than the prescribed dose suggests.
The AUA 2026 cohort exposes a flaw in how a lot of TRT is currently managed: clinics chase lab numbers and assume the patient will feel better when total testosterone hits 600 to 900 ng/dL.
Symptom resolution does not track lab values one-for-one. Men with identical 750 ng/dL totals can have radically different symptom profiles depending on:
The shape of the curve (steady gel level vs. injection peak/trough)
Free testosterone (which depends on SHBG, not just total)
This is why the modality choice matters. A man whose libido does not respond to a gel that puts his total T at 800 ng/dL may feel transformed on injections that put him at the same number. The drug is the same molecule, but the delivery profile is different — and his body responds to that profile.
What the Cohort Means for Clinic Choice
The single most actionable takeaway from the AUA 2026 data is this: pick a clinic that offers multiple modalities and is willing to switch you between them based on symptom response, not just lab values.
Many telehealth clinics default to one delivery method:
Some lock patients into proprietary creams or topical formulations
Some default to weekly injections without offering pellets or gels as alternatives
Some only prescribe clomiphene or enclomiphene, citing fertility preservation, even when symptoms are not improving
The right clinic should:
Start you on the modality that fits your goals (fertility-preserving, simple compliance, fast response)
Reassess at 3 months with both labs and a validated symptom inventory
Switch modality if symptoms are not resolving even with in-range labs
Add adjuncts (hCG, anastrozole) when the underlying issue is estradiol balance, not testosterone level
The AUA 2026 cohort separated symptom response by domain — and the picture is more nuanced than "injections win across the board."
Libido and erectile function. Injectable testosterone produced the largest gains. Clomiphene produced modest gains, partly limited by the estradiol response. Gels produced intermediate response, often dose-dependent.
Energy and fatigue. All three modalities helped, but injections again led. Clomiphene response was variable — some men felt better, others felt no change.
Mood and depressive symptoms. Smaller spread across modalities. Even modest testosterone elevation tends to improve mood scores. Gels and injections performed similarly here.
Body composition. Injections produced the largest changes in lean mass and fat distribution over 6 to 12 months, consistent with their higher average serum levels and stronger anabolic signal. See TRT before and after body composition for typical timelines.
The clinical implication: if your primary complaint is libido or sexual function, injections are likely your best first move. If your primary complaint is mood or modest energy, gel-first is reasonable. If you need fertility preservation, clomiphene or enclomiphene is the starting point — but expect a smaller symptomatic shift.
What This Does Not Tell Us
The AUA 2026 cohort has limits worth naming:
Real-world, not randomized. Men were not randomly assigned to modality. Doctors picked the formulation based on patient preference, contraindications, and insurance. This introduces selection bias that randomization would remove.
Symptom inventories vary by clinic. Different EHR systems used different symptom-tracking tools. The researchers harmonized as best they could, but the comparison is not as clean as a single-instrument randomized trial.
Dose was not standardized. Men on gels could have been underdosed. Men on clomiphene could have been on suboptimal regimens. The "best version" of each modality might perform differently than the average version.
No pellets or oral testosterone arm. The cohort focused on the three most common starting modalities. Pellets and oral testosterone undecanoate (oral testosterone — Jatenzo and Tlando review) are not covered here.
Despite these limits, the signal aligns with what experienced TRT clinicians have been saying for years: not all modalities are equal at the symptom level, even when they are equivalent at the lab level.
Practical Decision Framework
If you are starting TRT now or considering switching modality, the AUA 2026 data supports this framework:
Step 1: Define your primary symptom goal.
Libido and sexual function dominant -> consider injections first
Mood and energy primary, mild libido issue -> gel or injection both reasonable
Fertility preservation required -> enclomiphene or clomiphene first; switch if response is inadequate
Step 2: Set a realistic timeline.
4 to 6 weeks: early energy and mood response
8 to 12 weeks: libido response should be evident
12 weeks: re-check labs AND complete a structured symptom inventory
4 to 6 months: body composition and full clinical response
If labs are in range at 12 weeks but symptoms are not resolved, the AUA 2026 data says do not stay on the same modality at a higher dose. Switch. Most clinics underestimate how often this is the right move.
The old model: confirm low T, prescribe a default formulation, recheck labs at 3 months, move on.
The 2026 model: confirm low T, match modality to the patient's primary symptom and goals, recheck both labs and a structured symptom inventory at 3 months, and switch modality if response is inadequate.
The clinics that adopt this approach first will outperform — and the data suggests patients should expect it from any provider they choose.
References
American Urological Association 2026 Annual Meeting. IP22-08: Symptom Improvement Differs by Testosterone Therapy Modality in Men with Hypogonadism — A Real-World Cohort Analysis. May 15-18, 2026, Washington D.C. J Urol. 2026.
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432.
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. (TRAVERSE trial.)
Wheeler KM, Sharma D, Kavoussi PK, et al. Clomiphene Citrate for the Treatment of Hypogonadism. Sex Med Rev. 2019;7(2):272-276.
FDA. Potential New Indication for Testosterone Replacement Therapy. Federal Register. April 2026.
What did the AUA 2026 modality study actually find?
In a real-world cohort of 469 men with hypogonadism, symptom improvement was not equal across testosterone therapy modalities. Men on injectable testosterone reported the highest rates of symptomatic response. Men on clomiphene citrate reported lower symptom improvement, consistent with more modest testosterone elevation and a larger estradiol rise. Topical gels fell in between. The takeaway: the formulation you pick changes how you feel, not just your lab numbers.
Why do injections improve symptoms more than gels or clomiphene?
Three reasons. First, injections deliver a verifiable full dose -- gels lose 5 to 15 percent to skin transfer and absorption variability, and clomiphene depends on a functioning HPG axis to amplify the signal. Second, injection peak levels are higher, which drives stronger libido and energy response in many men. Third, dose titration is faster and cleaner with injections, so clinicians reach the optimal range sooner.
Does clomiphene work for hypogonadism symptoms?
Yes, but less reliably for symptoms than for lab numbers. Clomiphene raises endogenous testosterone by stimulating LH and FSH, but it also raises estradiol -- often disproportionately. The AUA 2026 cohort showed lower symptomatic response rates on clomiphene than on exogenous testosterone, particularly for libido and energy. It still has a role for men who want to preserve fertility, but expectations should be calibrated.
Should I switch from gel to injections if my symptoms are not resolving?
If your testosterone is in range on a topical gel but you still feel hypogonadal after 3 to 4 months, switching to injections is a reasonable next step. Many men feel substantially better on weekly or twice-weekly subcutaneous injections at the same serum testosterone level, likely because of differences in peak/trough dynamics and the avoidance of skin absorption variability. Discuss the switch with your clinic before stopping the gel.
Are pellets and oral testosterone covered in the AUA 2026 data?
The IP22-08 cohort focused primarily on injections, topical gels, and clomiphene citrate. Pellets and oral testosterone (testosterone undecanoate, oral) were not the main focus. Separate 2026 reviews of pellets and oral testosterone show distinct symptom response profiles -- pellets give steady levels but flexibility is limited, and oral testosterone undecanoate works well for many men but has tighter dosing requirements with food.
What does this mean for choosing a TRT clinic?
Pick a clinic that offers multiple modalities -- not just one. The clinics that lock you into a single delivery method (often a proprietary cream or pellet) are optimizing for their margins, not your symptom response. Compare clinics that let you switch modalities if the first one is not delivering symptomatic benefit. The clinic comparison tools at /clinics show which providers handle the full menu.
How long should I try one modality before switching?
Give each modality 3 to 4 months at a properly titrated dose with confirmed in-range labs. If symptoms have not improved by then, switching modality is reasonable. Many men cycle through gel first (because it is the conventional starting point), find symptoms only partially resolved, and then move to injections where response is more reliable. This is normal and expected with current evidence.
